[ad_1]
An international collaboration between scientists in the UK, Canada, and Brazil is set to revolutionize vaccine development by creating new technology that aims to accelerate the process and reduce costs. The project, funded by CEPI with £2.16 million, will focus on developing the MANGO (Manufacturing on the go) device at the University of Toronto to automate Virus-Like Particle (VLP) manufacturing.
Virus-like particles mimic viruses to trigger an immune response without containing viral material, but their production is slow as it requires living cells. The MANGO device will use cell-free expression to speed up manufacturing time from weeks to just one day. The collaboration with institutions like Imperial College London and the University of Leeds aims to cut development time dramatically, supporting CEPI’s goal to respond to new diseases within 100 days.
The innovative MANGO device could eliminate the need for traditional facilities, skilled workforce requirements, and cold chain storage, resulting in reduced costs and enabling regional manufacturing in Global South countries. The partnership between CEPI and CPI supports the 100 Days Mission, endorsed by G7 and G20 leaders, to reduce vaccine development timelines to just over three months.
The project aligns with CEPI’s commitment to equitable access to vaccines and ensuring availability to populations at risk during future outbreaks. Results from the collaboration will be published open access for the benefit of the global scientific community.
Source
Photo credit pharmatimes.com
